Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 3/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 3/20 | 0.32 |
| ▸ | RXRA | P19793 | 3/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24361017 | 0.93 | VCAM1 (0.38) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL24361103 | 0.84 | MAP2K2 (0.38) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL24360786 | 0.82 | ELANE (0.48) | ELANE | |
| SCHEMBL24360787 | 0.80 | VCAM1 (0.35) | VCAM1 | |
| SCHEMBL12903047 | 0.77 | GABRG2 (0.42) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL24360871 | 0.75 | GABRA1 (0.39) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL24360877 | 0.74 | ELANE (0.46) | ELANEVCAM1 | |
| SCHEMBL12942077 | 0.73 | GABRG2 (0.42) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL24361018 | 0.73 | VCAM1 (0.43) | VCAM1 | |
| SCHEMBL23559314 | 0.71 | PTPN1 (0.34) | GABRG2GABRB3GABRA5GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127225-A1 | ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127225-A1 | ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | CACNA1F, SLC6A5, IDUA | GABRG2 2792/4885GABRB3 3239/4885GABRA5 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.